Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pharmacia to Double Sales, Enter Top 10 in 2005: Mr Yamaki
July 1, 2002
- 75% of the Elderly Enjoy Healthy Life: White Paper
July 1, 2002
- Basic Policy for FY2003 Budget Formation Recommended by Council
July 1, 2002
- Expert Panel Presents Interim Report on IP
July 1, 2002
- REGULATORY NEWS IN BRIEF
July 1, 2002
- Good Initial Market Reactions to Olmesartan: Mr Shoda of Sankyo
July 1, 2002
- Number of ADRs Totals 26,545 in FY2001
July 1, 2002
- Wholesalers' Cooperation Is Essential in Immediate PMS: Teijin
July 1, 2002
- Clinical Research GL to Be Compiled by Korosho Working Group
July 1, 2002
- Nippon Chemiphar to Promote Uralyt Based on GLs
July 1, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 1, 2002
- Taiyo Pharm Aims at Sales of Over \20 Bil. in FY2002
July 1, 2002
- PMS Study to Verify Usefulness of Taiho's TS-1
July 1, 2002
- Sales of Radicut Exceed MPC's Expectation
July 1, 2002
- New GCP GL Fully Applied in Most Clinical Trials At Present
July 1, 2002
- DTC Advertisements in Japan Discussed: JPMA Seminar
July 1, 2002
- Report on New Drug Evaluation System Compiled by Study Group
July 1, 2002
- BUSINESS NEWS IN BRIEF
July 1, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
July 1, 2002
- WEBSITE NEWS
July 1, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…